STE

STRUCTURAL ANALYST NOTE: STERIS PLC (STE)

Date: 2026-06-20 Current Price: $202.61

1. Structural Readiness

• Conservative Entry: — (Not yet established; requires a confirmed breakout above the forming range high).
• Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation).
• Breakout Level: — (Pending definition of the range high).
• Extension: — (No extension data provided).
• ATR Context: Current ATR is 2.6% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 2.6% indicates moderate volatility suitable for position sizing, though not the highest historical volatility bucket).

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED
• Macro Thesis: None Named.
• Analysis: As of 2026-06-20, there is no named secular thesis attached to this specific setup. The conviction must be derived entirely from the quality of the structural setup (which is currently forming) and the underlying business fundamentals. Do not invent a macro narrative; judge the name on its execution of the current fiscal outlook and the structural readiness of the price action.

3. Business Fundamentals (Point-in-Time Evidence)

STERIS plc operates as a leading global provider of products and services supporting patient care, with a primary emphasis on infection prevention. The company is organized into three primary segments:

• Healthcare: Provides comprehensive offerings for healthcare providers, focusing on sterile processing departments (SPD) and procedural centers (OR and endoscopy suites). This segment reported 9% reported growth and 8% constant currency organic growth in the prior year, driven by a 12% growth in services and 7% growth in consumables.
• AST (Advanced Sterilization Technologies): Supports medical device and pharmaceutical manufacturers via a global network of contract sterilization, laboratory testing, and integrated sterilization equipment.
• Life Sciences: Offers products and services for biopharmaceutical and medical device research and manufacturing, specifically targeting aseptic manufacturing.

Key Financial & Operational Metrics (as of May 2026):

• Revenue Guidance: Management expects constant currency organic revenue growth of 6% to 7% for the total company for fiscal 2027.
• Margin Outlook: EBIT margins are anticipated to expand by approximately 50 basis points for fiscal 2027, positioned at the high end of their outlook.
• EPS Guidance: Fiscal 2027 earnings per share are projected at $11.10 to $11.30, representing 9% to 11% growth over fiscal 2026.
• Cash Flow: Free cash flow is expected to be $850 million in fiscal 2027, with Capital Expenditures (CapEx) of $375 million.
• Backlog: As of March 31, 2026, the total backlog stood at $490.7 million (up from ~$400 million in Q4 2025). This includes $392.1 million in Healthcare and $98.7 million in Life Sciences. The increase is attributed to shipment timing and acquisitions.
• Acquisitions: Two tuck-in acquisitions completed in the first nine months of fiscal 2026 (aggregate consideration ~$23.4 million) are expected to contribute $45 million in combined revenues to fiscal 2027.
• Legal Resolution: A significant liability overhang was addressed via a settlement agreement entered on October 29, 2025, resolving substantially all pending personal injury claims related to Ethylene Oxide (EO) sterilization for a payment of up to $48.2 million.

4. Archetype and Conviction

• Archetype: Quality Compounder
• Fit Analysis: The company fits the "Quality Compounder" archetype due to its consistent double-digit growth in services (12%), expanding margins (50 bps), and strong free cash flow generation ($850M). The business model is reinforced by a growing backlog ($490.7M) and a clear path to margin expansion through operational efficiency and acquisition integration.
• Conviction Stack:
• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts and SEC filings with clear guidance on revenue, margins, and EPS.
• Structural Quality: Moderate/Positive. The setup is "Forming," which is a positive signal but not a confirmed breakout. The ATR of 2.6% suggests manageable volatility.
• Setup Readiness: Partial. The price is holding above support, but the breakout has not fired.
• Rerating Potential: Moderate. The resolution of the EO litigation (a known overhang) combined with margin expansion and mid-single-digit procedure volume growth provides a fundamental basis for valuation support, though the setup itself is not yet confirmed.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A confirmed breakout above the forming range high (conservative entry) would confirm the setup. Fundamentally, evidence of the two new acquisitions exceeding the $45M revenue contribution or further margin expansion beyond the 50 bps target would strengthen the case.
• Gaps in Evidence:
• Sector Classification: The specific industry classification is missing from the data stream.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management guidance for 6-7% organic revenue growth and 9-11% EPS growth in fiscal 2027; resolution of EO litigation liability for $48.2 million; backlog growth to $490.7 million driven by acquisitions and shipment timing. Key risks: Setup remains in "forming" state with no confirmed breakout; no named macro thesis to provide secular tailwinds; potential for procedure volume growth to decelerate below mid-single digits. Sizing hint: Position size should reflect the "forming" status (partial signal) rather than a confirmed breakout; utilize the 2.6% ATR for volatility-based sizing. Expected path: Management expects margin expansion and steady revenue growth; the setup requires a price breakout above the forming range to confirm the structural thesis. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) and for fiscal 2027 guidance to be realized.